Wellington Management Group’s Aligos Therapeutics ALGS Stock Holding History
Bought
Maintained
Sold
Other funds holding ALGS
EC
VC
HA
VVM
BBA
NHAS
TCM
BC
Wellington Management Group's ALGS Position: Q2 2022 in Review
Wellington Management Group sold out of Aligos Therapeutics (ALGS) in Q2 2022, closing a stake of 18,846 shares — an estimated $1.01M sold.
Wellington Management Group first reported a position in ALGS in Q4 2020 and held it in 6 quarters. The position peaked at $107M in Q4 2020. 59 funds tracked by Wall St. Rank hold ALGS as of Q2 2022.
- Wellington Management Group reported no remaining Aligos Therapeutics position as of Q2 2022 after selling out during the quarter.
- Wellington Management Group sold 18,846 Aligos Therapeutics shares in Q2 2022, an estimated $1.01M.
- Wellington Management Group first reported a position in Aligos Therapeutics in Q4 2020 and held it in 6 quarters.
- Wellington Management Group's Aligos Therapeutics position peaked at $107M in Q4 2020.
- 59 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2022.
Based on Wellington Management Group's 13F filing for Q2 2022, filed 15 Aug 2022.